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Abstract g-secretase is responsible for the proteolysis of amyloid precursor protein (APP) into
short, aggregation-prone amyloid-beta (Ab) peptides, which are centrally implicated in the
pathogenesis of Alzheimer’s disease (AD). Despite considerable interest in developing g-secretase
targeting therapeutics for the treatment of AD, the precise mechanism by which g-secretase
produces Ab has remained elusive. Herein, we demonstrate that g-secretase catalysis is driven by
the stabilization of an enzyme-substrate scission complex via three distinct amino-acid-binding
pockets in the enzyme’s active site, providing the mechanism by which g-secretase preferentially
cleaves APP in three amino acid increments. Substrate occupancy of these three pockets occurs
after initial substrate binding but precedes catalysis, suggesting a conformational change in
substrate may be required for cleavage. We uncover and exploit substrate cleavage preferences
dictated by these three pockets to investigate the mechanism by which familial Alzheimer’s disease
mutations within APP increase the production of pathogenic Ab species.
DOI: 10.7554/eLife.17578.001
Introduction
Alzheimer’s disease (AD) is the most common form of dementia and currently the sixth leading cause
of death in the United States, with no disease-modifying therapeutics available. A central and patho-
logical hallmark of AD is the deposition of amyloid-beta (Ab) plaques in the brain (Hardy and Sel-
koe, 2002). These plaques are comprised of aggregates of Ab peptides, which are formed by the
sequential cleavage of the membrane embedded amyloid precursor protein (APP) by two pro-
teases—b-secretase first removes the ectodomain of APP, then g-secretase cleaves the remaining
C-terminal fragment within its transmembrane domain (TMD) to liberate Ab from cellular mem-
branes. Via its proteolytic component presenilin (Li et al., 2000; Wolfe et al., 1999), g-secretase
processes the TMD of APP into Ab peptides of differing lengths, mostly producing a more benign
Ab species 40 amino acids in length, termed Ab40, as well as lesser amounts of a longer, more
aggregation prone and pathogenic species, Ab42. The total amount of Ab42, as well as the ratio of
Ab42/40, are thought to be key mediators of Ab pathogenesis, a hypothesis strongly supported by
the fact that nearly all the 200-plus autosomal-dominant familial Alzheimer’s disease (FAD) mutations
in presenilin-1, -2 and APP increase the Ab42/40 ratio (see www.alzforum.org/mutations).
Due to the strong link between g-secretase catalyzed Ab formation and AD pathogenesis, the
development of g-secretase targeting therapeutics has been of high interest over the past two deca-
des (Golde et al., 2013; De Strooper, 2014). Both g-secretase inhibitors (GSIs) and a g-secretase
modulator (GSM), the latter working by an unknown mechanism to influence g-secretase to produce
shorter, presumably less pathogenic Ab species, have failed in recent clinical trials. The failure of
GSIs is due at least in part to toxicities from cleavage inhibition of other g-secretase substrates such
as Notch (Doody et al., 2013; Golde et al., 2013). Little is known about how g-secretase recognizes
the transmembrane domain of substrates, given that no consensus amino acid cleavage motif has
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been identified for the more than one hundred g-secretase substrates discovered to date
(Haapasalo and Kovacs, 2011). Unfortunately, the further development of safe and effective g-sec-
retase targeting therapeutics has been held back by a fundamental lack of understanding of how g-
secretase recognizes and cleaves the TMDs of its many substrates, especially APP. Elucidation of this
basic mechanism should at the very least add to our understanding of how Ab is produced and may
also aid in the development of safe and effective disease-modifying therapeutics.
Mass spectrometry studies have identified a complex mixture of products generated from g-sec-
retase’s cleavage of the transmembrane domain of APP (Matsumura et al., 2014). Looking at the
formation of these products over time, it is apparent that the TMD of APP is mostly processed via
two major pathways. g-secretase predominantly initiates endoproteolysis at a so-called epsilon (e)
cleavage site—after Leu49 or Thr48, generating Ab49 or Ab48 and two different APP intracellular
domains (AICD), AICD 50–99 or AICD 49–99, respectively (Kakuda et al., 2006; Sato et al., 2003).
Ab49 and Ab48 are then sequentially cleaved in increments of three amino acids to produce mostly
Ab40 and Ab42, respectively (Takami et al., 2009). The two major pathways are therefore Ab49 fi
Ab46 fi Ab43 fi Ab40 and Ab48 fi Ab45 fi Ab42 (Figure 1A) (Fernandez et al., 2014;
Takami et al., 2009). There are, however, other Ab species generated by g-secretase through usually
minor and sometimes overlapping, alternative pathways (Matsumura et al., 2014; Olsson et al.,
2014). Importantly a shorter peptide, Ab38, can be formed from both major pathways, originating
from Ab42 or Ab43 (Okochi et al., 2013). Additionally, a third, sparingly used site of e cleavage can
lead to the production of Ab47, which rather than being processed to Ab44 is instead mostly
cleaved to Ab43, subsequently generating Ab40 (Ab47 fi Ab43 fi Ab40) (Matsumura et al., 2014).
Normally, g-secretase uses the Ab49 fi Ab40 and the Ab48 fi Ab42 pathways to produce mostly
Ab40 and Ab42 via a stepwise, tripeptide cleavage process. The mechanism that dictates this pre-
ferred tripeptide cleavage (and thus the driving force behind g-secretase catalysis and Ab formation)
is completely unknown. In this study, we report that g-secretase tripeptide cleavage is driven by
three S’ pockets within the active site of the enzyme. We identify specific substrate cleavage prefer-
ences dictated by the three S’ pockets and exploit these preferences to determine the predominant
mechanism of each FAD mutation within the transmembrane domain of APP, including a novel
mechanism in which final cleavage products are uncoupled from initial e pathway preference.
eLife digest Individuals with Alzheimer’s disease generally have deposits known as “amyloid
plaques” in the brain. These plaques are made up of a mixture of molecules called amyloid beta
peptides that clump together and are thought to be a key cause of the disease. The amyloid beta
peptides vary in size; the larger peptides tend to be more prone to forming clumps than the smaller
ones and are thus more toxic to the brain.
An enzyme called gamma-secretase makes amyloid beta peptides by cutting up a protein called
APP. Proteins are made of chains of building blocks called amino acids and studies using a
technique called mass spectrometry show that gamma-secretase cuts APP in segments of three
amino acids at a time. The size of the amyloid beta peptides produced is determined by the
positions in APP that gamma-secretase selects to cut. Therefore, understanding how the enzyme
works could provide new opportunities for developing drugs to treat Alzheimer’s disease.
Here, Bolduc et al. found that the human gamma-secretase enzyme has sites that amino acids in
APP can bind to that help to guide the enzyme to cut APP by three amino acids at a time. These
binding sites control where the enzyme cuts APP and therefore determines which amyloid peptides
are produced. Previous studies have linked several naturally occurring mutations in the gene
encoding APP to inherited forms of Alzheimer’s disease. Bolduc et al. now reveal that several of
these mutations affect the places that gamma-secretase cuts APP to produce amyloid peptides.
These findings may be helpful for developing drugs that could manipulate gamma-secretase to
produce smaller, less harmful amyloid peptides. Gamma-secretase can cut many other proteins, and
so a future challenge will be to find out if the enzyme cuts these other proteins in the same way that
it cuts APP.
DOI: 10.7554/eLife.17578.002
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Results
When studying enzyme catalysis much focus is appropriately placed on determining how an enzyme
interacts with its substrate. However, oftentimes the manner in which an enzyme interacts with prod-
uct (in the form of product inhibition) can be equally informative with regard to its catalytic mecha-
nism. To this end, we asked whether the naturally produced tripeptide fragments of APP are
inhibitors of g-secretase. We found that all five tripeptides produced from the TMD of APP are




































Figure 1. Tripeptide fragments of APP inhibit g-secretase. (A) Schematic diagram of the major sequential cleavage
pathways of the transmembrane domain of APP (Ab49 fi Ab46 fi Ab43 fi Ab40 in red and Ab48 fi Ab45 fi Ab42
in blue). Mutations causing Familial Alzheimer’s disease are below the APP TMD in blue. (B) IC50 curves from the
inhibition of g-secretase activity by APP product tripeptide fragments. Mean ± SD, n = 2. (C) Noncompetitive
inhibition of g-secretase with VIV tripeptide, R2 = 0.98. (D) Yonetani-Theorell plot for the mutually exclusive
binding of VIV and the noncompetitive transition-state analog inhibitor III-31-C, R2 = 0.98. (E) Cartoon
representation of the three S’ pockets of presenilin (PSEN) along with three P’ amino acids of substrate and the
transition-state analog L685,458. (F) IC50 curves from the inhibition of g-secretase activity with FAF and AFA
synthetic tripeptides. Mean ± SD, n = 2.
DOI: 10.7554/eLife.17578.003
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~150 mM to several mM (Figure 1B). Although these binding affinities are too low for the tripeptides
to be involved in any form of biologically relevant feedback inhibition, we imagined the manner in
which they inhibit g-secretase could be instructive in elucidating the basic cleavage mechanism of
the protease. We characterized the mode of inhibition of the most potent of the tripeptides, VIV,
finding that these data fit well to a noncompetitive inhibition model, with a global R2 of 0.98
(Figure 1C). Given that the tripeptide segments of the TMD of APP must occupy the active site of g-
secretase during catalysis, we hypothesized that VIV may compete for the same binding site on the
enzyme as transition-state analogs. An inhibitor cross-competition analysis reveals this is likely true,
with a series of parallel lines resulting from a Yonetani-Theorell plot demonstrating mutually exclu-
sive binding of VIV and the transition-state analog III-31-C (Figure 1D).
We noticed that nearly all of the g-secretase targeting transition-state analog inhibitors devel-
oped to date (e.g. L685,458, III-31-C) contain essentially a tripeptide fragment C-terminal to the
transition-state-mimicking hydroxyl isostere (Figure 1E). Structure-activity relationship (SAR) studies
have demonstrated that transition-state analog inhibitors containing only two amino acids here are
relatively weak inhibitors compared to those comprised of three amino acids, while adding a fourth
amino acid does not achieve additional potency (Esler et al., 2004). This suggests that there are
three, and only three, putative S’ pockets in the presenilin active site that contribute to inhibitor
binding. Of note, the SAR studies also suggest that while the putative S1’ and S3’ pockets are large
and can accommodate amino acids of varying size, the S2’ pocket is small and inhibitors with an aro-
matic amino acid (phenylalanine) at this position have decreased potency by two orders of magni-
tude compared to those with less bulky aliphatic amino acids (Esler et al., 2004).
We imagined that the tripeptide APP TMD products may be binding these three putative S’ pock-
ets to achieve inhibition. In agreement with this hypothesis, a synthetic tripeptide of the predicted
optimal binding sequence (FAF, to fit in the large-small-large S1’-S2’-S3’ pockets) was a more potent
inhibitor of g-secretase activity than any of the naturally occurring APP-derived tripeptides, while a
peptide predicted to clash with this binding site (AFA) is a very weak inhibitor, even at mM concen-
trations (Figure 1F).
Based on these results, we reasoned that the three putative S’ pockets within the g-secretase
active site are likely occupied by substrate prior to hydrolysis of the scissile bond as a means for g-
secretase to stabilize a transition-state-like scission complex with substrate. This would provide a
simple mechanism for the preferred cleavage of APP in three amino acid increments, as well as pro-
vide an explanation for why g-secretase mostly sticks to each major pathway, producing Ab40 or
Ab42 after initiating cleavage of APP at either the L49 or T48 e sites, respectively. Additionally, given
that substrate movement in the form of helical unwinding is thought to be a required step in the
poorly defined intramembrane protease cleavage mechanism (Akiyama et al., 2015; Dickey et al.,
2013; Fluhrer et al., 2012; Moin and Urban, 2012; Urban and Freeman, 2003; Ye et al., 2000),
the three S’ pockets could potentially provide a means for g-secretase to stabilize its helical sub-
strate in a more cleavable conformation, thereby lowering the activation energy required for
catalysis.
To test this hypothesis, we took advantage of the fact that the putative S2’ pocket of g-secretase
is apparently small and has a reduced ability to accommodate a bulky amino acid such as phenylala-
nine. We predicted that we should be able to selectively decrease cleavage of either the Ab49 fi 40
pathway or the Ab48 fi 42 pathway simply by placing an aromatic amino acid at the P2’ position of
APP at the initial e cut site. In other words, an aromatic amino acid placed at V50 should reduce e
cleavage after T48, thereby lowering the amount of Ab42 produced, thus decreasing the Ab42/40
ratio. Conversely, an aromatic amino acid at M51 should reduce e cleavage after L49, lowering the
amount of Ab40 produced and therefore increase the Ab42/40 ratio (Figure 2A).
In an in vitro assay using purified g-secretase to cleave recombinant C100-FLAG APP-based sub-
strate, V50F and V50W both decreased the Ab42/40 ratio, while the same substitutions at M51
increased the Ab42/40 ratio as predicted (Figure 2B). MALDI/TOF mass spectrometry (MS) analysis
of the corresponding AICD fragment revealed the complete elimination of AICD 49–99 for V50F and
of AICD 50–99 for M51F (Figure 2C). Interestingly, in addition to the expected AICD fragments,
both V50F and M51F are also cleaved to a minor extent after I47, producing AICD 48–99. The rea-
son for this is unknown, although g-secretase may be compensating for reduced cleavage through
one of the two major pathways. Previous MS studies have demonstrated that the majority of Ab47 is
eventually processed to Ab40, through an Ab43 intermediate (Matsumura et al., 2014).
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Figure 2. Selective blocking of the Ab40 or Ab42 pathways with aromatic amino acids placed at the P2’ position of
e cleavage. (A) Schematic diagram of the TMD of APP with pathway blocking aromatic amino acid mutations at the
P2’ position for the T48 or L49 e cleavage. (B) In vitro Ab42/40 ratios with Phe or Trp mutations at V50 or M51. Ab
measured using Ab40 and Ab42 ELISA kits from Invitrogen. Mean ± SD, n = 3, t-test **<0.01, ****<0.0001. (C)
MALDI/TOF MS of the AICD fragments generated from in vitro cleavage of C100: WT (AICD 50–99, expected
mass: 6905.6, observed mass: 6907.4; AICD 49–99, expected mass: 7018.8, observed mass: 7021.3). V50F (AICD
50–99, expected mass: 6953.8, observed mass: 6949.8; AICD 48–99, expected mass: 7167.9, observed mass:
7163.5). M51F (AICD 49–99, expected mass: 7034.8, observed mass: 7030.1; AICD 48–99, expected mass: 7135.8,
observed mass: 7131.8). (D) Ab42/40 ratios measured from the media of HEK cells transfected with V50 mutants.
Ab levels measured by 6E10 ELISA. Mean ± SD, n = 3, t-test **<0.01, ***<0.001, ****<0.0001. (E) Ab42/40 ratios
measured from the media of HEK cells transfected with M51 mutants. Ab levels measured by 6E10 ELISA. Mean ±
Figure 2 continued on next page
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We obtained similar results measuring secreted Ab after transiently transfecting HEK cells with
full-length APP containing mutations at V50 or M51. Here, all mutations tested at V50 caused a
reduction in the Ab42/40 ratio, although none as robustly as the bulky aromatic amino acids Phe, Tyr
and Trp (Figure 2D). And while mutations of smaller amino acids at M51 caused modest reductions
in the Ab42/40 ratio, aromatic substitutions here all caused substantial increases in the Ab42/40 ratio
(Figure 2E). As predicted by our model, there was a significant reduction in Ab42 production for the
V50 aromatic substitutions, with little change in the Ab40 levels (Figure 2F). There was a similar pre-
dicted reduction in Ab40 for the M51 aromatic mutants; however, we also see an increase in Ab42
levels here (Figure 2F), likely because the normally less used Ab48 fi 42 pathway is compensating
for the reduced flux through the preferred Ab49 fi 40 pathway, as these mutants all produced
roughly equivalent amounts of total Ab (Figure 2G).
Because each tripeptide cleavage event requires the reading of three amino acids of substrate at
a time (as dictated by the three S’ pockets), we reasoned we should be able to predictably shift the
Ab42/40 ratio by placing a Phe in the P2’ position at each tripeptide cleavage event along the two
major pathways (Figure 3A). As expected, Phe substitutions at V44 and I47 decreased the Ab42/40
ratio, while Phe mutations at I45 and T48 increased the Ab42/40 ratio (Figure 3B and C). The pre-
dicted Ab42/40 shifts were nearly identical whether Ab levels were measured from an in vitro assay
(Figure 3B) or from a cell-based assay (Figure 3C). These results are of particular note, as I45F is a
known FAD mutation (Guerreiro et al., 2010), likely indicating that the mechanism of this mutation
is the Phe positioned in the P2’ position at the Ab43 cut site, blocking cleavage of APP through the
less pathogenic Ab49 fi 40 pathway and favoring the pathogenic Ab48 fi 42 pathway. The Phe at
I45 also lies in the S3’ position for Ab42 cleavage, likely making the precursor to Ab42 production a
better substrate for g-secretase through a favorable P3’-S3’ interaction. Mutating A42 to Phe
completely blocked the formation of Ab40 in agreement with our model (Figure 3D), while still
allowing for the production of other Ab species (Figure 3—figure supplement 1).
Although we expected the Phe substitutions at V44, I45, I47 and T48 to be acting independently
of the pathway chosen at initial e cleavage, an alternative explanation for the above results is that
these mutations instead influence e cleavage in favor of the final Ab products measured. To investi-
gate this possibility, we utilized an antibody that specifically recognizes the free N-terminus of AICD
50–99 (Chávez-Gutiérrez et al., 2012), and therefore the initiation of the Ab49 fi 40 pathway. Sur-
prisingly, all four of these mutants actually caused a shift in e cleavage toward the initiation of the
opposite pathway. Although V44F and I47F cause reductions in the Ab42/40 ratio, they shifted initial
e cleavage away from the Ab49 fi 40 pathway—nearly completely eliminating AICD 50–99. And
while I45F and T48F increased the Ab42/40 ratio, they shifted e cleavage more in favor of AICD 50–
99 compared to WT (Figure 3E). These AICD species were confirmed by mass spectrometry
(Figure 3F).
To explore further the apparent ability of tripeptide cleavage preference to dissociate the normal
connection between initial e cleavage and final g cleavages, we made double Phe mutants in which
the e cut site is controlled with a Phe at either V50 or M51, while placing a conflicting Phe at V44,
I45, I47 or T48 in the initial pathway. Measuring Ab secreted from transfected HEK cells, we clearly
saw the double mutants behave almost identically to the single point mutants N-terminal to the e
cut site (Figure 4A and B). MS of the AICD fragments revealed the expected and complete blocking
of AICD 49–99 or AICD 50–99 for the V50F and M51F containing double mutants, respectively
(Figure 4C). Together these data suggest final g cleavages can be completely uncoupled from initial
e cleavages.
Single Phe mutations at V46 and L49 both caused modest increases in the Ab42/40 ratio. We pre-
dicted that since these mutations do not occupy the S2’ pocket for either major pathway, V46F and
L49F when paired with a neighboring Phe mutation should behave like its neighboring Phe mutant
alone. Indeed, L49F-V50F had a reduced Ab42/40 ratio compared to WT like V50F alone, while
Figure 2 continued
SD, n = 3, t-test ***<0.001, ****<0.0001. (F) Ab40 and Ab42 levels for aromatic substitutions at V50 and M51
normalized to WT. Ab levels measured by 6E10 ELISA. Mean ± SD, n = 3, t-test *<0.05, ***<0.001, ****<0.0001. (G)
Total secreted Ab levels (see Materials and methods) from the aromatic mutations at V50 and M51.
DOI: 10.7554/eLife.17578.004
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Figure 3. Phenylalanine mutations at P2’ positions predictively shift the Ab42/40 ratio. (A) Schematic diagram of
Phe mutations at P2’ positions at cut sites within the TMD of APP and the expected Ab42/40 changes compared
to WT. (B) In vitro Ab42/40 ratios from g-secretase cleavage of recombinant C100-FLAG substrates. Ab measured
using Ab40 and Ab42 ELISA kits from Invitrogen. Mean ± SD, n = 3, t-test *<0.05, **<0.01. (C) Ab42/40 ratios from
Ab secreted from HEK cells. Ab levels measured by 6E10 ELISA. Mean ± SD, n = 3, t-test **<0.01, ***<0.001,
****<0.0001. (D) Ab40 levels measured from the conditioned media of HEK cells transfected with WT or A42F APP.
Ab levels measured by 6E10 ELISA. Mean ± SD, n = 3. (E) Western blot analysis of the AICD fragments generated
from V44F, I45F, I47F and T48F in vitro. Total AICD was measured with anti-FLAG M2 antibody (green). Ab49 fi
Ab40 pathway preference was measured with an antibody specifically recognizing the N-terminus of AICD 50–99
fragment (red). (F) MALDI/TOF MS confirmation of the AICD fragments measured in (E): V44F (AICD 49–99,
expected mass: 7018.8, observed mass: 7020.8), V45F (AICD 50–99, expected mass: 6905.6, observed mass: 6906.2;
Figure 3 continued on next page
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T48F-L49F had an elevated Ab42/40 ratio comparable to T48F (Figure 4D). Likewise, V46F-I47F dis-
played a reduced Ab42/40 ratio similar to I47F alone, while I45F-V46F had a drastically increased
Ab42/40 ratio like I45F alone (Figure 4D).
To this point, aromatic amino acids placed in the P2’ position at each tripeptide cleavage site
within the TMD of APP caused a predictable outcome without exception. We therefore reasoned
that placing two phenylalanines in tandem, such that there is a Phe in the P2’ position at both major
e cut sites, should reduce overall cleavage. As predicted, a double mutant of V50F-M51F caused a
sharp reduction in total AICD formation compared to WT and the V50F and M51F single point muta-
tions alone (Figure 5A). However, AICD formation from V50F-M51F cleavage was not completely
abolished; rather, its rate of production was markedly reduced (Figure 5B). This suggests g-secre-
tase has a means by which to overcome two aromatic amino acids in a row, which would seemingly
conflict with its cleavage preferences.
The observation that both tripeptide cleavage products of APP and transition-state analog inhibi-
tors are noncompetitive inhibitors of g-secretase suggests that the subsites on g-secretase for initial
substrate binding and subsequent catalysis are spatially separate and distinct, meaning substrate
movement is likely required after initial substrate binding but prior to catalysis. This would be in
agreement with previous reports suggesting there may be an exosite on g-secretase to which sub-
strate initially binds prior to translocating to the active site for cleavage (Kornilova et al., 2003,
2005). It would also agree with studies of other intramembrane cleaving proteases, which have pro-
posed substrate movement in the form of helical unwinding is a prerequisite for catalysis
(Akiyama et al., 2015; Dickey et al., 2013; Fluhrer et al., 2012; Moin and Urban, 2012;
Urban and Freeman, 2003; Ye et al., 2000).
Given that the S’ pockets within the active site are likely the second binding site for substrate, we
reasoned that although the V50F-M51F mutant cannot be hydrolyzed as efficiently as WT, it should
still be effectively bound by g-secretase in an initial docking site. Co-IP of WT and V50F-M51F C100
in complex with g-secretase reveals equal amounts of substrate bound, suggesting both substrates
have a similar binding affinity for the enzyme (Figure 5C). Furthermore, myc-tagged V50F-M51F was
just as effective as myc-tagged WT C100 at competing for g-secretase cleavage of FLAG-tagged WT
C100 (Figure 5D), again indicating V50F-M51F and WT substrate initially interact with g-secretase in
a similar manner. Together this suggests that the two Phe mutations in V50F-M51F do not affect ini-
tial recognition or binding of the C100 substrate, but rather may reduce the stabilization of a cleav-
able intermediate enzyme-substrate complex by clashing with the S’ pockets in the presenilin active
site.
We noticed that in addition to being processed more slowly, V50F-M51F also produced a sharply
lower Ab42/40 ratio compared to WT (Figure 5E). To determine why this was occurring, we per-
formed MS on the AICD fragment. Surprisingly, we found that e cleavage was initiated almost exclu-
sively after I47 (the very next available cleavage site), generating a 48–99 AICD fragment
(Figure 5F), indicating g-secretase is capable of skipping the two phenylalanines to initiate cleavage,
albeit at a slower rate. Ab47 is primarily processed to Ab40 (Ab47 fi Ab43 fi Ab40)
(Matsumura et al., 2014), accounting for the decreased Ab42/40 ratio.
Although g-secretase usually cleaves APP in increments of three amino acids to produce predomi-
nantly Ab40 and Ab42 in the mechanism outlined in this study, a seemingly unusual cleavage devi-
ates from the tripeptide preference to produce Ab38 in appreciable quantities (Okochi et al., 2013;
Takami et al., 2009). To determine if production of Ab38 occurs through the same three S’ pockets
used by g-secretase to achieve tripeptide cleavage, we transiently transfected HEK cells with mutant
APP containing a single Phe point mutant at V39, V40, I41 or A42. Measuring secreted Ab38
Figure 3 continued
AICD 49–99, expected mass: 7018.8, observed mass 7020.1), I47F (AICD 49–99, expected mass: 7018.8, observed
mass: 7019.5), T48F (AICD 50–99, expected mass: 6905.6, observed mass: 6907.4; AICD 49–99, expected mass:
7018.8, observed mass: 7019.5).
DOI: 10.7554/eLife.17578.005
The following figure supplement is available for figure 3:
Figure supplement 1. Total Ab from the A42F mutant.
DOI: 10.7554/eLife.17578.006
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Figure 4. Phenylalanine mutations in the P2’ position of the last read tripeptide segment dictates final pathway
preference. (A) Ab42/40 ratios from HEK cells of V44F-M51F and I47F-M51F double mutants behave like single Phe
mutants V44F and I47F, respectively. Ab levels measured by 4G8 ELISA. Mean ± SD, n = 3, t-test **<0.01,
***<0.001. (B) Ab42/40 ratios from HEK cells of I45F-V50F and T48F-V50F double mutants behave like single Phe
mutants I45F and T48F, respectively. Ab levels measured by 4G8 ELISA. Mean ± SD, n = 3, t-test *<0.05, **<0.01,
***<0.001, ****<0.0001. (C) MALDI/TOF MS conformation of the elimination of AICD 49–99 and AICD 50–99 for
the V50F and M51F containing double Phe mutants, respectively. V44F-M51F (AICD 49–99, expected mass: 7034.8,
observed mass: 7030.7; AICD 47–99 expected mass: 7249.0, observed mass: 7253.7), I45F-V50F (AICD 50–99,
expected mass: 6953.8, observed mass: 6950.1; AICD 48–99, expected mass: 7167.9, observed mass: 7164.6), I47F-
M51F (AICD 49–99, expected mass: 7034.8, observed mass: 7032.2; AICD 47–99, expected mass: 7283.0, observed
mass: 7280.1), T48F-V50F (AICD 50–99, expected mass: 6953.8, observed mass: 6949.4; AICD 48–99, expected
mass: 7214.0, observed mass: 7209.4). (D) Ab42/40 ratios from HEK cells transfected with double Phe mutations in
tandem. Ab levels measured by 6E10 ELISA. Mean ± SD, n = 3, t-test **<0.01, ***<0.001, ****<0.0001.
DOI: 10.7554/eLife.17578.007
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revealed that V40F almost completely eliminated Ab38 production (Figure 6A), demonstrating occu-
pancy of the three S’ pockets is required for Ab38 formation. V39F and I41F both sharply increased
Ab38, a result we interpret as the phenylalanine mutations making the precursor to Ab38 a better
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Figure 5. Phenylalanine blocking mutations at both e cleavage sites reduces APP cleavage but not binding to g-
secretase. (A) Western blot of g-secretase cleavage of WT, V50F, M51F and V50F-M51F C100-FLAG. Duplicates
from each substrate represent separate independent data points. * denotes a degradation product which co-
purified with the substrate. (B) Cleavage of WT and V50F-M51F C100-FLAG over time. (C) Co-immunoprecipitation
of Myc-tagged WT or V50F-M51F C100 substrate. Duplicates are from separate pull-down experiments. * antibody
light chain. (D) Competitive cleavage of WT C100-FLAG by WT C100-Myc or V50F-M51F C100-Myc. (E) Ab42/40
ratio of the V50F-M51F double mutant. Mean ± SD, n = 3, t-test, ****<0.0001. (F) MALDI/TOF MS of the AICD
fragment from the V50F-M51F mutant: (AICD 51–99, expected mass: 6822.5, observed mass: 6817.1; * unknown
peak, observed mass: 7030.4; AICD 48–99, expected mass: 7183.9, observed mass: 7179.2; AICD 47–99, expected
mass: 7297.1, observed mass: 7292.5, AICD 46–99, expected mass: 7396.2, observed mass: 7396.1).
DOI: 10.7554/eLife.17578.008
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Figure 6. g-Secretase preferentially cleaves APP near the helix-destabilizing Gly-Gly motif. (A) Ab38 levels from
HEK cells transiently transfected with V39F, V40F, I41F or A42F APP. Ab levels measured by 4G8 ELISA. Mean ±
SD, n = 3. (B) Ab42/40 ratios from V44F-I47F-V50F and I45F-T48F-M51F triple mutants from transiently transfected
HEK cells. Ab levels measured by 4G8 ELISA. Mean ± SD, n = 3, t-test, ****<0.0001. (C) Ab38, Ab40 and Ab42
levels from HEK cells transfected with V44F-I47F-V50F and I45F-T48F-M51F triple mutants, the V44F-I45F double
mutant and the hexa-mutant V44F-I45F-I47F-T48F-V50F-M51F. Ab levels measured by 4G8 ELISA. Mean ± SD, n =
3. (D) Schematic diagram of sequential Phe mutants in the TMD of APP. (E) Ab38 + 40 + 42 secreted from HEK
cells transiently transfected with the mutants from (D). Ab levels measured by 4G8 ELISA. Mean ± SD, n = 3, t-test
***<0.001, ****<0.0001. (F) Ab42/40 ratios from (E). Ab levels measured by 4G8 ELISA. Mean ± SD, n = 3, t-test
*<0.05, ****<0.0001.
DOI: 10.7554/eLife.17578.009
Figure 6 continued on next page
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amino acids (Esler et al., 2004). A42F produces about as much Ab38 as WT, indicative of the lack of
a contributory S4’ pocket.
During the course of this study, we found that three phenylalanines sequentially mutated in the
P2’ positions of each major pathway (V44F-I47F-V50F and I45F-T48F-M51F) caused a very strong
reduction or elevation in the Ab42/40 ratio in the predicted direction (Figure 6B). As expected, the
shifts were caused by the near complete elimination of Ab42 for the V44F-I47F-V50F mutant and of
Ab40 for the I45F-T48F-M51F mutant (Figure 6C). Interestingly, in each case, Ab38 levels were pro-
duced in amounts comparable to or greater than WT. This demonstrates that Ab38 is capable of
being produced from both the Ab49 fi 40 and Ab48 fi 42 pathways, in perfect agreement with
recent MS studies that identified the precursors to Ab38 as being either Ab43 or Ab42
(Matsumura et al., 2014; Olsson et al., 2014). Surprisingly, when we blocked the production of
both Ab43 and Ab42 at the same time with a V44F-I45F double mutant we not only did not prevent
the production of Ab38, but rather Ab38 levels were drastically increased (Figure 6C). Even after
blocking the first six major cleavage sites (V44F-I45F-I47F-T48F-V50F-M51F) of APP, we still observe
elevated Ab38 compared to WT, demonstrating g-secretase is fully capable of traversing multiple
phenylalanines within APP to find the especially labile amide bond between G38 and V39. It is likely
that the helix-destabilizing Gly-Gly motif at G37 and G38 is the reason for this observation, making
the G38-V39 bond particularly accessible for cleavage.
Next, we attempted to determine how many phenylalanines in a row g-secretase was capable of
skipping by taking advantage of the fact that the GG motif apparently allows for g-secretase to devi-
ate from normal sequential tripeptide cleavage. Astonishingly, even after increasing the number of
phenylalanines in a row to eight, g-secretase was still able to produce Ab above mock transfected
levels (Figure 6D,E). The V44F)M51F mutant produced mostly Ab38 (Figure 6—figure supple-
ment 1), in what may be a single endoproteolytic cleavage event, although we have not been able
to obtain enough AICD for MS confirmation. Predictably, the Ab42/40 ratios for these mutants fol-
low a pattern expected if g-secretase cleaves at the next available site after each additional Phe
(Figure 6F).
Using our newfound knowledge of the basic cleavage mechanism of g-secretase, and our ability
to precisely control it with phenylalanine mutations, we next decided to investigate the mechanism
of FAD mutations within the TMD of APP, which all increase the Ab42/40 ratio to different degrees.
There are more than a dozen missense FAD mutations targeting this region of APP (Figure 1A), with
the majority being located N-terminal and downstream of e cleavage. To date, the currently
accepted explanations for how these mutations increase the Ab42/40 ratio are: 1) affecting the posi-
tioning/helical stability of the g-secretase bound APP TMD such that initial e cleavage is shifted
toward T48, thus favoring the production of Ab42 (Chávez-Gutiérrez et al., 2012; Chen et al.,
2014; Dimitrov et al., 2013); or 2) influencing the reaction kinetics of g-secretase’s processing of
APP, leading to incomplete carboxy-trimming and therefore increased Ab42 over the more proc-
essed Ab38 (Chávez-Gutiérrez et al., 2012) (Figure 7A). As demonstrated above with the I45F FAD
mutant, we now show that a third possible mechanism exists, in that sequence-specific cleavage
preferences can uncouple initial e cleavage and final g cleavages of APP (Figure 7A).
To determine the prevalence of the two previously proposed mechanisms and to possibly identify
additional pathway uncoupling mutants, we made each FAD mutant within the APP TMD alone and
as a double mutant with V50F. The V50F mutation would be predicted to block e cleavage after T48
independent of the FAD mutant’s affect on subsequent cleavage events. We would therefore predict
that if an FAD mutant causes an increase in the Ab42/40 ratio by influencing initial e cleavage or by
affecting subsequent carboxy-trimming along the Ab48 fi 42 pathway, then that same FAD mutant
when paired with V50F should produce a reduced Ab42/40 ratio compared to WT, similar to V50F
alone. Conversely, if an FAD mutant affects subsequent cleavage events independent of e cleavage,
Figure 6 continued
The following figure supplement is available for figure 6:
Figure supplement 1. HEK cell expression and Ab production from consecutive phenylalanine APP mutants.
DOI: 10.7554/eLife.17578.010
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Figure 7. The tripeptide cleavage mechanism of g-secretase and the effect of APP transmembrane domain FAD
mutations. (A) The three mechanisms by which FAD mutations within the TMD of APP increase the Ab42/40 ratio.
1) Mutations shift initial e cleavage towards the Ab42 pathway. 2) Mutations reduce cleavage of the third cleavage
event, producing more Ab42 over the more processed Ab38. 3) Cleavage specific preferences cause switching
from the Ab40 to the Ab42 pathway, as exemplified by the I45F FAD mutant. (B) The Ab42/40 ratio of each FAD
mutation with and without an additional V50F mutation to control the e cleavage site. The majority of mutations
are rescued by the V50F substitution suggesting that these FAD mutations increase the Ab42/40 ratio by
influencing e cleavage and/or affecting carboxy-trimming. I45F, I45T and T48P retain significantly elevated ratios,
indicating these mutants dissociate initial e and final g cleavages. Ab levels measured by 4G8 ELISA. Mean ± SD, n
= 3, t-test ***<0.001, ****<0.0001.(C) The tripeptide cleavage mechanism of g-secretase. After initial substrate
binding, we speculate that the helical TMD of substrate unwinds into the active site of presenilin (PSEN) where it is
Figure 7 continued on next page
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causing uncoupling of initial e cleavage and final g cleavages, then the FAD-V50F double mutant
should retain an elevated Ab42/40 ratio, similar to the FAD mutant alone.
Screening nearly all the FAD mutants within the TMD of APP by this method, we found that the
majority were either completely or nearly completely rescued when paired with V50F (Figure 7B,
Figure 7—figure supplement 1), resulting in 42/40 ratios significantly less than WT. This suggests
the predominant mechanism of elevating the Ab42/40 ratio by FAD mutants within the TMD of APP
is by shifting the preference of initial e cleavage from the Ab40 to the Ab42 pathway, and/or by influ-
encing carboxy-trimming. This may have been predicted, given that I45F is the only aromatic amino
acid mutation to fall in the S2’ pocket of one of the major cleavage pathways. The only other FAD
mutation containing an aromatic amino acid, V46F, falls within the S1’ and S3’ pockets for the Ab42
and Ab40 pathways, respectively, therefore never clashing with the S2’ pocket and not influencing
the Ab42/40 ratio as a major pathway blocker. However, we found that in addition to I45F, there are
two other mutants, I45T and T48P, which appear to dissociate the normal connection between initial
pathway preference and final cleavage products.
V50F partially rescues the Ab42/40 ratio when paired with I45T, but remains significantly elevated
compared to WT, indicating the I45T mutant both influences initial e cleavage and uncouples e from
g cleavages. The change in e cleavage preference of I45T was verified using the AICD 50–99 specific
antibody (Figure 7—figure supplement 2), showing a small reduction in AICD 50–99. Interestingly,
the I45T mutant reduces the amount of AICD 50–99 comparable to I45V, even though these two
mutants display very different Ab42/40 ratios. This again suggests I45T dissociates cleavage down-
stream of e to achieve such a high Ab42/40 ratio. Exactly how I45T does this is currently unknown
and requires further investigation.
The T48P-V50F double mutant behaves identically to T48P alone. Given that proline is a helix-
breaking amino acid, the T48P mutant may not undergo normal e cleavage after P48 or L49. Deter-
mining how T48P increases the 42/40 ratio and overcomes the e controlling V50F mutant will require
further investigation.
Discussion
In this study, we identify that three S’ amino acid binding pockets guide the productive positioning
of substrate into the g-secretase active site, providing the mechanism behind the enzyme’s preferred
tripeptide cleavage of APP and pathogenic Ab production. Based on the data reported herein (dis-
cussed further below) and numerous other studies of g-secretase (Das et al., 2003; Kornilova et al.,
2003, 2005) and other intramembrane proteases (Akiyama et al., 2015; Dickey et al., 2013;
Fluhrer et al., 2012; Moin and Urban, 2012; Urban and Freeman, 2003; Ye et al., 2000), we spec-
ulate that after initial binding to g-secretase, substrate must undergo a translocation and/or confor-
mational change in order to bind the three S’ pockets within the active site and subsequently be
cleaved by the enzyme (Figure 7C). After initial endoproteolysis, the three S’ pockets guide further
carboxy-trimming of the retained Ab species until it is short enough to dissociate from the complex,
producing predominantly Ab38, Ab40 and Ab42.
Figure 7 continued
stabilized by the three S’ pockets in the catalytic pocket prior to cleavage. Successive carboxy tripeptide trimming
occurs until the eventual release of Ab peptide. (D) g-secretase cleavage of the transmembrane domain of Notch
from Okochi et al, 2002.
DOI: 10.7554/eLife.17578.011
The following figure supplements are available for figure 7:
Figure supplement 1. APP FAD mutant panel measured by 6E10 ELISA.
DOI: 10.7554/eLife.17578.012
Figure supplement 2. AICD fragments for the three I45 FAD mutants determined by western blot using the AICD
50–99 specific antibody.
DOI: 10.7554/eLife.17578.013
Figure supplement 3. Secreted Ab levels from V40F, A42F and V44F.
DOI: 10.7554/eLife.17578.014
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More than a decade ago, SAR studies of g-secretase-targeting transition-state analogs putatively
assigned three S’ pockets to the active site of the enzyme (Esler et al., 2004). Transition-state ana-
logs containing only two amino acids for S’ pocket binding inhibited g-secretase less effectively, indi-
cating that occupancy of the S3’ pocket is required for a strong interaction. This likely provides the
reason why g-secretase only cleaves APP in segments of three or more amino acids, but never two.
The preference for cleaving three amino acids originates from the lack of a contributory fourth S’
pocket. A fourth amino acid (no matter the size) added to a transition state inhibitor neither
increased nor decreased the inhibitors potency (Esler et al., 2004), suggesting a fourth S’ pocket
doesn’t contribute to g-secretase-inhibitor or -substrate interactions.
To support our proposed model, we exploited the fact that the second of the three S’ pockets is
apparently too small to readily accommodate an aromatic amino acid. We generated dozens of sub-
strates containing aromatic amino acid substitutions in the P2’ positions at each cleavage site along
the Ab40 or Ab42 pathways, selectively blocking each individual cleavage event. Without exception
we were able to predict the shift in the Ab42/40 ratio. This was accomplished both in vitro with puri-
fied g-secretase and recombinant C100 substrate as well as in a cell-based assay, transiently trans-
fecting mutant full-length APP in HEK cells and measuring secreted Ab. The same predicted Ab42/
40 ratio changes were observed in vitro and in the cell-based assay whether we measured Ab (6E10
detection antibody) or Ab plus p3 products (4G8 detection antibody) by ELISA. Together this dem-
onstrates we are probing the fundamental mechanism by which g-secretase cleaves APP, irrespective
of mutant effects on cellular localization, g-secretase’s interaction with activity-modulating proteins/
lipids within the cell or any artifacts that may arise from more artificial in vitro assays.
Although we are unable to measure every cleavage product from the ~70 mutant forms of APP
we generated, we do note that every time a Phe was placed in the P2’ position of a cleavage prod-
uct that we could readily and directly measure, there were almost negligible amounts of that prod-
uct formed. For example, in the cell-based assay, V40F, A42F and V44F generated levels of Ab38,
Ab40 and Ab42, respectively, that were actually less than mock transfected levels (Figure 7—figure
supplement 3). These Ab levels are orders of magnitude less than that from WT APP transfected
cells, although we cannot say whether these low levels of Ab species were produced from endoge-
nous HEK cell APP or from our transfected mutants. Similarly, we were unable to detect by MS any
AICD products containing a Phe in the P2’ position. Together, these data suggest that aromatic
amino acids may be completely excluded from the S2’ pocket and further demonstrates that sub-
strate occupancy of the three S’ pockets is an absolute requirement for catalysis.
It is likely that phenyalanine substitutions at various positions along the transmembrane domain
of APP influence the general structure and/or helical stability of the substrate. This could affect the
manner in which these substrates interact with g-secretase. Given that we are able to accurately pre-
dict the Ab42/40 ratio without exception for the dozens of mutants used in this study, we expect
that cleavage preferences dictated by the presence of aromatic amino acids in the P2’ position are
overriding any affect these mutations have on substrate helical structure/stability and any altered
manner in which these mutant substrates initially interact with the enzyme. This is directly supported
in Figure 3 where V44F, I45F, I47F and T48F all shift initial e cleavage in favor of the opposite path-
way relative to the final cleavage products measured and originally predicted by our model.
We present several lines of evidence suggesting that substrate movement and/or a substrate con-
formational change after initial enzyme binding is an important step in g-secretase’s catalytic mecha-
nism. We identify that like transition-state analogs, tripeptide cleavage products are noncompetitive
inhibitors of g-secretase, albeit very weak inhibitors. By definition this means the binding sites on g-
secretase for initial substrate binding and subsequent catalysis are spatially separate, requiring sub-
strate movement after initial binding to be an integral part of g-secretase’s catalytic mechanism. For
rhomboid, a recent study demonstrates that product-mimicking peptide aldehydes are non-competi-
tive inhibitors of this serine intramembrane protease (Cho et al., 2016), exactly like tripeptide prod-
ucts and transition-state analog inhibitors are for g-secretase, suggesting a common two-step
mechanism between these two intramembrane proteases.
Additionally, the double Phe mutant V50F-M51F, which is predicted by our model to sterically
clash with the three S’ pockets in the active site, is still efficiently bound to g-secretase even though
it is processed less efficiently than WT. Given that this mutant effectively competes for g-secretase
processing of other substrates, it must bind to the initial docking site on the enzyme for substrate.
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This suggests that binding to the S’ pockets is the final step in substrate recognition and positioning
within the enzyme prior to catalysis.
Furthermore, we are unable to prevent the formation of Ab38 by specifically blocking the produc-
tion of the known Ab38 precursors Ab42 and Ab43; instead, paradoxically the V44F-I45F double
mutant increases Ab38 production. It is likely that the helix-destabilizing Gly-Gly motif at G37 and
G38 is the reason for this observation. Local helical unwinding around this position probably makes
the amide bond between G38 and V39 particularly accessible for cleavage, and this may be the rea-
son for g-secretase’s normal deviation from the preferred tripeptide cleavage for Ab38 production.
However, further investigation, including quantification of the intramembrane peptide products by
mass spectrometry, will be required to prove this. In the absence of a g-secretase—substrate co-
complex structure, it will not be possible to definitively prove the existence of a partially unwound
substrate intermediate. Conceivably, it should be possible to capture such an intermediate with a
transition-state analog covalently linked to the C-terminus of an APP- or notch-based helical
substrate.
Given that tripeptide cleavage is dictated by the three S’ pockets in the active site of presenilin,
we expect that other g-secretase substrates will be similarly cleaved preferentially in increments of
three amino acids, while skipping aromatic amino acids that fall in the S2’ pocket along the way, and
with cleavage occurring preferentially in helix-destabilized regions. This is important to note given
that many of g-secretase’s substrates naturally contain aromatic amino acids. The TMD of notch, for
example, naturally contains three phenylalanines. We know from a previous MS study that these phe-
nylalanines are skipped by g-secretase in a pattern consistent with our model (Figure 7D)
(Okochi et al., 2002).
In a recent study, we have demonstrated that substrates with large ectodomains have a reduced
binding affinity for g-secretase due to steric clashing with the nicastrin component of the g-secretase
complex (Bolduc et al., 2016). Based on this, and results from our current study, we might expect
that g-secretase can chose its substrates through a complex interplay between ectodomain length,
helical TMD stability and the sequence of amino acids (specifically aromatic amino acids) within sub-
strate TMD. There may even exist non-substrates containing short ectodomains but having stable
helices that are further protected from cleavage by sequential stretches of aromatic amino acids.
Whether such non-substrates exist, and the relationship between ectodomain size, helical stability
and amino acid sequence will require further investigation.
We show that the majority of FAD mutants within the TMD of APP primarily increase the Ab42/40
ratio by changing e cleavage, favoring the Ab48 fi 42 pathway. This is mostly in agreement with pre-
vious studies (Chávez-Gutiérrez et al., 2012; Chen et al., 2014; Dimitrov et al., 2013; Quintero-
Monzon et al., 2011). However, we also identify a new mechanism by which certain FAD mutations
can increase the production of pathogenic Ab species. Here, final g cleavages are uncoupled from
initial pathway preference determined by e cleavage. In the case of the I45F FAD mutation, the bulky
Phe sterically clashes with the S2’ pocket of g-secretase at the Ab43 cleavage site, blocking its cleav-
age and the subsequent production of Ab40. It is likely that the positioning of the Phe in the S3’
pocket of the Ab42 cleavage also enhances g-secretase proteolysis at this position through a favor-
able S3’-P3’ interaction. These two interactions likely combine to account for the fact that no other
mutation within the TMD of APP produces as much Ab42 as I45F. This is the most severe APP FAD
mutation, with an onset of clinical AD at 31 years of age (Guerreiro et al., 2010). There are at least
two additional FAD mutations, I45T and T48P, that appear to dissociate the e and g cleavages. How
these mutations accomplish this is currently unknown.
Our data also help explain previous observations in the literature. Prior to the identification of
presenilin as being the protease responsible for g-secretase activity (Wolfe et al., 1999), Lich-
tenthaler et al. performed a phenylalanine scanning study of the TMD of APP. In their study, they
observed the exact same Ab42/40 shifts identified here for several of the same mutants
(Lichtenthaler et al., 1999). Later, Sato et al. found that g-secretase was unable to cleave through
stretches of 3–5 consecutive tryptophans inserted into the TMD of APP (Sato et al., 2005). These
observations are now explained by the determination that the small S2’ pocket of g-secretase cannot
accommodate aromatic amino acids.
With the identification of the key role the three S’ pockets play in g-secretase’s cleavage mecha-
nism, several important new questions are raised. The exact locations of the three S’ pockets in pre-
senilin are currently unknown. Additionally, the identity of the initial substrate-binding site on
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presenilin is unknown. The resolution of enzyme—substrate and/or -inhibitor co-complexes by cryo-
EM will be informative in this regard. All enzymatic assays in this study utilized purified g-secretase
complex containing presenilin-1. It will be interesting to see if presenilin-2 has similar substrate
cleavage preferences. A major unsolved question pertains to the mechanism by which substrate
TMD is repositioned within g-secretase after each cleavage event in order to be close enough to the
active site for the next round of catalysis to occur. Is this a ratcheting or sliding motion? Is this an
active process or based on Brownian motion? At present, we do not know how g-secretase is capa-
ble of skipping stretches of several phenylalanines in a row. Determining how g-secretase accom-
plishes this may help elucidate how substrate moves during normal sequential cleavage.
Now that we have identified several key aspects of g-secretase’s substrate recognition and cleav-
age mechanisms, as well as provide valuable new tools for future structural and biochemical studies,
we should be able design experiments to elucidate some of g-secretase’s remaining unanswered
functional questions. The answers from which should have further broad implications for our under-




The following antibodies were used: a-Myc (9E10 Santa Cruz #sc-40), a-Flag (M2 Sigma #F3165), a-
Nct (Cell Signaling 3632S), a-GAPDH (Cell Signaling Technology, ab125247), a-APP (C7), a-AICD
50–99 (Rb) was a kind gift from Philip Szekeres at Eli Lilly, a-Ms 800nm (Licor Bio 926–32212) and a-
Rb 680nm (Licor Bio 926–68021). Tripeptides were synthesized by Anaspec corp. Total brain lipid
extract was from Avanti Polar Lipids (#131101). The following Ab ELISA kits were used: 4G8 (Meso
Scale Diagnostics, K15199E) or 6E10 (Meso Scale Diagnostics, K15200E) for cell-based assays; Ab40
(#KHB3482) and Ab42 (#KHB2442) ELISA kits from Invitrogen for in vitro assays.
Cloning
All mutant forms of C100 FLAG or full-length APP were generated by site directed mutagenesis of
either C100-FLAG in pET22b or full-length WT APP in the pCMV695 plasmid.
Tissue culture and transfection of adherent cells
Adherent HEK cells were cultured in complete growth media: Dulbecco’s Modified Eagle’s Medium
(DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 10 Units/mL penicillin,
and 10 mg/mL streptomycin. For transfection, adherent HEK cells were seeded in six-well dishes at a
density of 5x105 cells per well. Transfection was carried out with Lipofectamine 3000 reagent in
serum-free conditions with Opti-MEM I. Cells were incubated for 24 hr, at which time conditioned
media was harvested for ELISA and cells were harvested for western blot.
Growth and purification of g-secretase from HEK cells
Suspension HEK cells were cultured in 100 mL of unsupplemented Freestyle 293 media (Life Tech-
nologies, 12338-018) with shaking at 125 rpm, and passaged at a density of 2  106 cells/mL. For
transfection, suspension HEK cultures were grown to a density of 2  106 cells/mL. Media was
replaced with fresh Freestyle 293 media. 5 mL Freestyle 293, 150 mg of g-secretase vector containing
presenilin 1 (provided by Yigong Shi), and 450 mg of 25-kDa linear polyethylenimines (PEI) was mixed
and incubated for 30 min at room temperature. The DNA/PEI solution was then added to the HEK
culture and cells were grown for ~60 hrs prior to harvesting. g-secretase was purified as previously
described (Fraering et al., 2004; Osenkowski et al., 2009)
Purification of C100-FLAG substrates
C100-FLAG substrates were expressed in BL21 E. coli for 3 hrs at 37˚C after induction with 1 mM
IPTG. Cells were then pelleted and lysed by French press in 50 mM HEPES pH 7.0, 1% Triton X-100
detergent. FLAG-tagged substrates were then isolated by immunoprecipitation for 3 hrs at 4˚C with
anti-FLAG M2 beads from Sigma. Substrates were then eluted from the beads with 100 mM glycine
pH 2.5, 0.25% NP40 prior to being neutralized with tris buffer and stored at -80˚C.
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In vitro g-secretase assay
Purified g-secretase was incorporated into vesicles by first dissolving total brain lipid extract
(1.25 mM final) in 50 mM HEPES pH 7.0, 150 mM NaCl, 0.25% CHAPSO. g-Secretase (5–30 nM final
concentration) was then added to the solution and detergent removed by mixing SM-2 biobeads (62
mg/mL) (Bio-Rad) with the lipid/detergent/enzyme solution for two hrs at 4˚C. Biobeads were
removed from the newly formed proteoliposomes and reactions were initiated with the addition of
purified recombinant substrate C100-FLAG substrate. Reactions were quenched with SDS loading
dye for western blot or centrifuged for ELISA or mass spectrometry on Ab or AICD fragments,
respectively.
For inhibition studies, tripeptide fragments or inhibitors were dissolved in DMSO prior to being
diluted into the reaction buffer. The concentration of C100-FLAG used in all in vitro assays was 500
nM unless otherwise stated.
Ab ELISA
Conditioned media from HEK cells transfected with WT or mutant APP was assayed for Ab by 4G8
or 6E10 Ab ELISA kits from Meso Scale Diagnostics. Ab levels were measured by both 6E10 and 4G8
ELISA for each data point, yielding nearly identical results. In vitro assay Ab was measured using
Ab40 and Ab42 ELISA kits from Invitrogen. All ELISAs were performed according to the manufac-
ture’s protocols.
Co-immunoprecipitation of purified g-secretase and substrate
Purified g-secretase (5 nM final concentration) was preincubated in assay buffer (50 mM HEPES pH
7.0, 150 mM NaCl, 0.25% CHAPSO, 0.1% DOPC and 0.025% DOPE, 2% BSA) in the presence of
2 mM III-31C for 1 hr at room temperature. Purified WT or mutant C100-Myc (20 nM final concentra-
tion) was then incubated with g-secretase for 1 hr prior to pull down with anti-HA magnetic affinity
beads for 4 hr with mixing at room temperature. The immunoprecipitated complex was then washed
three times and eluted with SDS loading buffer prior to western blot with an anti-Myc antibody.
Kinetic analysis







where vi is the initial velocity in the presence of inhibitor at concentration ½I and vo is the initial
velocity in the absence of inhibitor.
Tripeptide inhibition was globally fit to the following noncompetitive equation:
v¼
Vmax S½ 







where, v is the initial rate, Ki is dissociation constant for inhibitor binding to free enzyme, Kii is the
dissociation constant for inhibitor binding to the enzyme-substrate complex.










I½  J½ 
aKiKj
 
where, vij is the initial rate in the presence of inhibitors, v0 is the initial rate in the absence of inhibi-
tor, Ki and Kj are the dissociation constants for inhibitors I and J, respectively. a = ¥ for inhibitors
which bind in a mutually exclusive fashion, while a = 1 for inhibitors which have distinct binding
sites.
Total Ab ELISA
Conditioned media was collected from transiently-transfected adherent HEK cells. Each well of an
uncoated 96-well multi-array plate (Meso Scale Discovery, #L15XA-3) was coated with 30 mL of a PBS
solution containing 3 mg/mL of 266 capture antibody (Elan), and incubated at room temperature
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overnight. A detection antibody solution was prepared with 3D6B detection antibody (Elan), 100 ng/
mL Streptavidin Sulfo-TAG (Meso Scale Discovery, #R32AD-5), and 1% MSD Blocker A (#R93BA-4) in
wash buffer (#R61TX-1). Following overnight incubation, 25 mL/well of sample, followed by 25 mL/
well of detection antibody solution were incubated for 2 hr at room temperature with shaking at
>300 rpm, washing wells with wash buffer between incubations. Plate was read and analyzed
according to manufacturer protocol.
Immunoprecipitation-Mass spectrometry (IP-MS)
Following an in vitro proteoliposome activity assay, AICD-FLAG products were isolated by immuno-
precipitiation with anti-FLAG M2 magnetic beads from Sigma. Completed reactions were incubated
with 50 mL of M2 beads in 10 mM MES pH 6.5, 10 mM NaCl, 0.05% DDM detergent in 500 mL vol-
umes overnight at 4˚C. AICD was then eluted from the beads with acetonitrile:water (1:1) with 0.1%
trifluoroacetic acid. MALDI/TOF mass spectrometry was performed with sinapinic acid matrix on a
calibrated ultraflextreme MALDI/TOF/TOF from Bruker in linear mode.
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